British authorities have authorized French drugmaker Valneva to produce a coronavirus vaccine for adults despite the government’s decision last year to cancel orders for at least 100 million doses of the vaccine.

The UK was the first country to approve the Valneva vaccine, which is also under review by the European Medicines Agency. Britain’s medicines regulator said Thursday that the two-dose vaccine is for adults aged 18 to 50, with the second dose being given about a month after the first.

The Valneva vaccine is made using technology that was used decades ago to produce flu and polio vaccines. This is the sixth COVID-19 vaccine the UK has cleared, and the only one that uses a “kill” virus; scientists grow the coronavirus in the lab and then inactivate the virus so that it cannot replicate or infect cells.

The U.K. government in September scrapped a deal with Valneva to buy at least 100 million doses of the vaccine, saying at the time that U.K. regulators might not approve the plan. The UK cancelled the deal due to supply issues, Valneva said.

Health Minister Sajid Javid said in September that he could not disclose details due to commercial concerns, but the deal surged because “it is also clear to us that the vaccine that the company is developing will not be approved.”

The UK, an early backer of the Valneva vaccine, agreed to invest millions of pounds in a production facility in Scotland. As part of the contract, the UK has agreed to buy 100 million doses, with an option for an additional 90 million doses.

Even without the Valneva vaccine, the government got enough doses to fully vaccinate everyone in the country twice. Nearly 60% of the UK population has so far received three doses of the vaccine.